

Please type a plus sign (+) inside this box → ☐



Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number 10/802,220  
Filing Date March 17, 2004  
First Named Inventor Sunami et al.  
Group Art Unit 1614  
Examiner Name Unassigned  
Attorney Docket Number 227833

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
/A.P./	EK	4,346,277		Wojtecki et al.	Aug. 24, 1982	
/A.P./	EL	4,444,784		Hoffman et al.	Apr. 24, 1984	
/A.P./	EM	4,681,893		Roth	Jul. 21, 1987	
/A.P./	EN	5,011,930		Fujikawa et al.	Apr. 30, 1991	
/A.P./	EO	5,030,447		Joshi et al.	Jul. 9, 1991	
/A.P./	EP	5,180,589		Joshi et al.	Jan. 19, 1993	
/A.P./	EQ	5,260,440		Hirai et al.	Nov. 9, 1993	
/A.P./	ER	5,273,995		Roth	Dec. 28, 1993	
/A.P./	ES	5,354,772		Kathawala	Oct. 11, 1994	
/A.P./	ET	5,356,896		Kabadi et al.	Oct. 18, 1994	
/A.P./	EU	5,622,985		Olukotun et al.	Apr. 22, 1997	
/A.P./	EV	5,686,104		Mills et al.	Nov. 11, 1997	
/A.P./	EW	5,916,595		Chen et al.	Jun. 29, 1999	
/A.P./	EX	5,969,156		Briggs et al.	Oct. 19, 1999	
/A.P./	EY	RE36,481		Inamine et al.	Jan. 4, 2000	
/A.P./	EZ	RE36,520		Smith et al.	Jan. 18, 2000	
/A.P./	FA	6,080,778		Yankner et al.	Jun. 27, 2000	
/A.P./	FB	6,126,971		Mills et al.	Oct. 3, 2000	
/A.P./	FC	6,242,003		Kalb et al.	Jun. 5, 2001	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

## **OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
/A.P./	FD	INAZU et al., <i>Current Opinion in Investigational Drugs</i> , 4(3): 291-297 (March 1, 2003)		
/A.P./	FE	WIERZBICKI, <i>Expert Opinion on Emerging Drugs</i> , 8(2): 365-376 (2003)		

Examiner Signature


/Anna Pagonakis/

Date Considered

08/28/2007

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/802,220
Filing Date	Mar. 17, 2004
First Named Inventor	Sunami et al.
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	227833
Client Reference Number	JF-133US

Sheet 1 of 1

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
/A.P./	FH	10/802,280		Urata et al.		Mar. 17, 2004
/A.P./	FI	10/825,531		Shinkai et al.		Apr. 15, 2004
/A.P./	FJ	10/835,916		Urata et al.		Apr. 30, 2004

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
/A.P./	FK	EP	0 992 496	A1	PFIZER PRODUCTS INC.	Apr. 12, 2000		
/A.P./	FL	EP	1 269 994	A2	PFIZER PRODUCTS INC.	Jan. 2, 2003		
/A.P./	FM	WO	00/17164	A1	PFIZER PRODUCTS INC.	Mar. 30, 2000		
/A.P./	FN	WO	03/000235	A1	PFIZER PRODUCTS INC.	Jan. 3, 2003		
/A.P./	FO	WO	03/063832	A1	PFIZER PRODUCTS INC.	Aug. 7, 2003		
/A.P./	FP	WO	2004/082593	A2	JAPAN TOBACCO INC.	Sep. 30, 2004		
/A.P./	FQ	WO	2004/082675	A1	JAPAN TOBACCO INC.	Sep. 30, 2004		
/A.P./	FR	WO	2004/098583	A1	JAPAN TOBACCO INC.	Nov. 18, 2004		

## **OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**

Examiner Signature

/Anna Pagonakis/


Date Considered

08/28/2007

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/802,220
Filing Date	March 17, 2004
First Named Inventor	Sunami et al.
Group Art Unit	1614
Examiner Name	Unassigned
LVM Reference Number	227833
Attorney Docket Number	JF-133US

Sheet 1 of 4

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
/A.P./	AI	3,576,830		Fukumaru et al.	Apr. 27, 1971	
/A.P./	AJ	4,740,438		Krishnamurthy	Apr. 26, 1988	
/A.P./	AK	4,853,319		Krishnamurthy et al.	Aug. 1, 1989	
/A.P./	AL	5,118,583	A	Kondo et al.	Jun. 2, 1992	
/A.P./	AM	5,194,539	A	Charmot et al.	Mar. 16, 1993	
/A.P./	AN	5,217,859	A	Boettcher et al.	Jun. 8, 1993	
/A.P./	AO	5,219,721	A	Klaus et al.	Jun. 15, 1993	
/A.P./	AP	5,350,667	A	Singer et al.	Sep. 27, 1994	
/A.P./	AQ	5,405,969	A	Wright et al.	Apr. 11, 1995	
/A.P./	AR	5,446,207	A	Pomponi et al.	Aug. 29, 1995	
/A.P./	AS	5,504,097	A	Malamas et al.	Apr. 2, 1996	
/A.P./	AT	5,512,548	A	Kushwaha et al.	Apr. 30, 1996	
/A.P./	AU	5,519,001	A	Kushwaha et al.	May 21, 1996	
/A.P./	AV	5,534,529	A	Yoshida et al.	Jul. 9, 1996	
/A.P./	AW	5,542,974	A	Buding	Aug. 6, 1996	
/A.P./	AX	5,556,888	A	Koda et al.	Sep. 17, 1996	
/A.P./	AY	5,614,550	A	Yoshida et al.	Mar. 25, 1997	
/A.P./	AZ	5,654,134	A	Morimura et al.	Aug. 5, 1997	
/A.P./	BA	5,698,564	A	Katsuyama et al.	Dec. 16, 1997	
/A.P./	BB	5,776,951	A	Arrowsmith et al.	Jul. 7, 1998	
/A.P./	BC	5,880,095	A	Park et al.	Mar. 9, 1999	
/A.P./	BD	5,925,645	A	Schmidt et al.	Jul. 20, 1999	
/A.P./	BE	5,932,587	A	Schmeck et al.	Aug. 3, 1999	
/A.P./	BF	6,069,148	A	Schmidt et al.	May 30, 2000	
/A.P./	BG	6,093,573	A	Beamer et al.	Jul. 25, 2000	
/A.P./	BH	6,127,383	A	Schmidt et al.	Oct. 3, 2000	
/A.P./	BI	6,140,342	A	Goldstein et al.	Oct. 31, 2000	
/A.P./	BJ	6,140,343	A	DeNinno et al.	Oct. 31, 2000	
/A.P./	BK	6,147,089	A	DeNinno et al.	Nov. 14, 2000	
/A.P./	BL	6,147,090	A	DeNinno et al.	Nov. 14, 2000	
/A.P./	BM	6,197,786	B1	DeNinno et al.	Mar. 6, 2001	
/A.P./	BN	6,207,671	B1	Schmidt et al.	Mar. 27, 2001	
/A.P./	BO	6,313,142	B1	Damon et al.	Nov. 6, 2001	
/A.P./	BP	6,362,198	B1	Goldstein et al.	Mar. 26, 2002	
/A.P./	BQ	6,395,751	B1	DeNinno et al.	May 28, 2002	
/A.P./	BR	6,448,295	B1	Sikorski et al.	Sep. 10, 2002	
/A.P./	BS	6,462,091	B1	Keller et al.	Oct. 8, 2002	
/A.P./	BT	6,753,346	B2	Shinkai et al.	Jun. 22, 2004	

Examiner Signature	/Anna Pagonakis/	Date Considered	08/28/2007
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/802,220
				Filing Date	March 17, 2004
				First Named Inventor	Sunami et al.
				Group Art Unit	1614
				Examiner Name	Unassigned
				LVM Reference Number	227833
Sheet	2	of	4	Attorney Docket Number	JF-133US

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
/A.P./	BU	2001/0018446	A1	Sikorski et al.	Aug. 30, 2001	
/A.P./	BV	2002/0103225	A1	Curatolo et al.	Aug. 1, 2002	
/A.P./	BW	2004/0039018	A1	Ruggeri	Feb. 26, 2004	
/A.P./	BX	2004/0053842	A1	Nguyen et al.	Mar. 18, 2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
/A.P./	BY	CA	2,000,631	A	Engels	Apr. 15, 1990		
	BZ	ES	2 127 690	B1	Universidad de Granada	Apr. 16, 1999		X*
	CA	EP	0 796 846	A1	BAYER AG	Sep. 24, 1997		X*
	CB	EP	0 818 197	A1	BAYER AG	Jan. 14, 1998		X*
	CC	EP	0 818 448	A1	BAYER AG	Jan. 14, 1998		X*
	CD	JP	45-11132		Sumitomo Chemical Company	Apr. 22, 1970		X*
	CE	JP	47-35786		Oouchi-Shinkou-Chemical Company	Sep. 8, 1972		X*
	CF	JP	1-321432		Konica Corp.	Dec. 27, 1989		X*
	CG	JP	1-278543		San Shin Kagaku Kogyo KK	Nov. 8, 1989		X*
	CH	JP	2-23338		Fuji Photo Film Co., Ltd.	Jan. 25, 1990		X*
	CI	JP	3-226750		Konica Corp.	Oct. 7, 1991		X*
	CJ	JP	9-59155	A2	KAKEN PHARMACEUTICAL CO LTD	Mar. 4, 1997		X*
	CK	JP	10-287662	A2	THE KITASTO INSTITUTE	Oct. 27, 1998		X*
/A.P./	CL	WO	92/03408	A1	RHONE-POULENC RORER LIMITED	Mar. 5, 1992		
/A.P./	CM	WO	92/03412	A2	RHONE-POULENC RORER LIMITED	Mar. 5, 1992		
/A.P./	CN	WO	96/30761	A1	WARNER-LAMBERT COMPANY	Oct. 3, 1996		
/A.P./	CO	WO	96/09406	A1	UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES	Mar. 28, 1996		
/A.P./	CP	WO	98/04528	A2	BAYER CORPORATION	Feb. 5, 1998		
/A.P./	CQ	WO	98/04528	A3	BAYER CORPORATION	Nov. 11, 1999		
/A.P./	CR	WO	98/23593	A1	PFIZER INC.	Jun. 4, 1998		
	CS	WO	98/34920	A1	BAYER AKTIENGESSELLSCHAFT	Aug. 13, 1998		X*
	CT	WO	98/35937	A1	JAPAN TOBACCO INC.	Aug. 20, 1998		X*
	CU	WO	98/39299	A1	BAYER AKTIENGESSELLSCHAFT	Sep. 11, 1998		X*
/A.P./	CV	WO	99/14204	A1	G.D. SEARLE & CO.	Mar. 25, 1999		
/A.P./	CW	WO	99/41237	A1	G.D. SEARLE & CO.	Aug. 19, 1999		

Examiner Signature	/Anna Pagonakis/	Date Considered	08/28/2007
--------------------	------------------	-----------------	------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Application Number	10/802,220
Filing Date	March 17, 2004
First Named Inventor	Sunami et al.
Group Art Unit	1614
Examiner Name	Unassigned
LVM Reference Number	227833
Attorney Docket Number	JF-133US

Sheet	3	of	4
-------	---	----	---

[illegible]

/Anna Pagonakis/

08/28/2007

- \* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Sheet	4	of	4
-------	---	----	---

**Examiner  
Initials**

Doc.  
No.

Translation	
M	

**Yes**

No\*

D R	ANTONOVA et al., <i>Comptes rendus de l'Academie bulgare des Sciences</i> , 46(1), 71-74 (1993)
-----	-------------------------------------------------------------------------------------------------

**X**

D S	CONNOLLY et al., <i>Biochemical and Biophysical Research Communications</i> , 223(1), 42-47 (1996)
-----	----------------------------------------------------------------------------------------------------

D T	DE GROOTH et al., <i>XIV International Symposium on Drugs Affecting Lipid Metabolism</i> , 47 (2001)
-----	------------------------------------------------------------------------------------------------------

DU	DE GROOTH et al., <i>Circulation, Supplement II</i> , 104(17), 848 (2001)
----	---------------------------------------------------------------------------

DV	DROZD, Zhurnal Organicheskoi Khimii, 23(2), 355-365 (1987)
----	------------------------------------------------------------

---

X

DW	EGAN et al., <i>Advances in Prostaglandin, Thromboxane, and Leukotriene Research</i> , 11, 151-157 (1983)
----	-----------------------------------------------------------------------------------------------------------

D X	HORI et al., <i>Heterocycles</i> 9(10), 1413-1418 (1978)
-----	----------------------------------------------------------

DY	HUANG et al., <i>Clinical Science</i> , 103(6), 587-594 (2002)
----	----------------------------------------------------------------

D Z	MAEDA et al., <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 14, 2589-2591 (2004)
-----	------------------------------------------------------------------------------------------

E A	NAGARAJAN et al., <i>Indian Journal of Chemistry</i> , 12(3), 227-235 (1974)
-----	------------------------------------------------------------------------------

EB	OKAMOTO, <i>Lipid</i> , 13(1), 76-81 (2002)
----	---------------------------------------------

**X**

E C	OKAMOTO, <i>BIO Clinica</i> , 18(5), 429-432 (2003)
-----	-----------------------------------------------------

$$\frac{1}{x^2}$$

E D	OKAMOTO et al., <i>European Journal of Pharmacology</i> , 466(1-2), 147-154 (2003)
-----	------------------------------------------------------------------------------------

EE	SHIMOJI et al., <i>Atherosclerosis</i> , 172(2), 247-257 (2004)
----	-----------------------------------------------------------------

E F	SHINKAI, Naibunpi, Tonyobyoka, 12(4), 364-369 (2001)
-----	------------------------------------------------------

$$X^+$$

E G	SIMOV et al., <i>Khimiya Geterotsiklicheskikh Soedinenii</i> , 9, 1192-1195 (1976)
-----	------------------------------------------------------------------------------------

$$x^*$$

EH	WAKITANI et al., <i>The Knowledge Foundation's 2<sup>nd</sup> International Conference on HDL Cholesterol Metabolic Pathways and Drug Development</i> , 1 (2001)
----	------------------------------------------------------------------------------------------------------------------------------------------------------------------

EI	WATTS, <i>Clinical Science</i> , 103(6), 595-597 (2002)
----	---------------------------------------------------------

EJ	WCN Working Group on Cardiovascular Research, <i>Slide Presented at the 15<sup>th</sup> Annual Scientific WCN Meeting, Amsterdam, The Netherlands</i> (December 2002)
----	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Examiner Signature**

/Anna Pagonakis/

Date Considered

08/28/2007

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/802,220
				Filing Date	March 17, 2004
				First Named Inventor	SUNAMI, Masaki
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	227833

U.S. PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date If Appropriate
		Patent Number	Kind Code					
/A.P./	AA	6,426,365		Shinkai et al.	07-30-2002			

FOREIGN PATENT DOCUMENTS										
Examiner Initials <sup>1</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No <sup>*</sup>

OTHER - NON PATENT LITERATURE DOCUMENTS									
Examiner Initials <sup>1</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.						Translation	
								Yes	No*
/A.P./	AB	de GROOTH et al., <i>Circulation</i> , 105, 2159-2165 (May 7, 2002).							
/A.P./	AC	KATO et al., <i>J. Biol. Chem.</i> , 264, 4082-4087 (March 5, 1989).							
/A.P./	AD	KOBAYASHI et al., <i>Atherosclerosis</i> , 162, 131-135 (2002).							
/A.P./	AE	OKAMOTO et al., <i>Nature</i> , 406, 203-207 (July 13, 2000).							
/A.P./	AF	SHIMADA et al., <i>J. Chromatogr. B</i> , 659, 227-241 (September 23, 1994).							
/A.P./	AG	SHINKAI et al., <i>J. Med. Chem.</i> , 43, 3566-3572 (September 21, 2000).							
/A.P./	AH	TOLLEFSON et al., <i>Methods Enzymol.</i> , 129, 797-816 (1986).							
/A.P./	AI	U.S. Code of Federal Regulations, Title 21, Section 320.1 (2001 ed.).							
/A.P./	AH	WELLING, <i>Clin. Pharmacokinet.</i> , 9 (1), 404-34 (January/February 1984).							

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Anna Pagonakis/	Date Considered	08/28/2007
-----------------------	------------------	--------------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.